PharmPK Discussion - Formulation for dog studies (IV/PO)

• On 31 Oct 2014 at 11:45:35, Florence Raynaud (Florence.Raynaud.-a-.icr.ac.uk) sent the message
  

  
  Dear all,
  
  Can anyone recommend formulations that are routinely used for dog PK (iv/po). We hardly carry out
  these studies and would appreciate some help.
  Many thanks.
  Florence.
  
  Florence I Raynaud BPharm, PhD
  Group leader DMPK
  Cancer Research UK Cancer Therapeutics Unit
  Division of Cancer Therapeutics
  The Institute of Cancer Research
  15 Cotswold Road
  Sutton, Surrey SM2 5NG
  
  

  Back to the Top

• On 31 Oct 2014 at 11:58:10, Kristin Grimsrud (kngrimsrud.at.ucdavis.edu) sent the message
  

  
  Hello,
  This question is a bit vague. What first needs to be asked is what is the question you are trying to
  answer? Are you doing a bioavailability study where you need both iv and po routes? It sounds like
  that may be that case. Is this a drug that is already developed for these routes or do you need to
  have it compounded?
  And in terms of formulation for PO what is the intended use for this drug? Is it a liquid
  suspension, oral tablet, time-released tablet???
  
  Hope these questions will help guide you in determining what you are actually trying to ask. The
  group will be able to assist you better if you could clarify your question.
  
  Take care,
  
  --
  Kristin Grimsrud, DVM, PhD
  
  Department of Surgery
  School of Medicine
  University of California, Davis
  
  

  Back to the Top

• On 2 Nov 2014 at 16:05:12, Dr. Kurani (kurani.at.themismedicare.com) sent the message
  

  
  Hello,
  Sorry  for intervention.
  Question arises  whether  both route of administration is needed for PK studies  and for regulatory
  submission?
  if the oral  study is available, would it suffice if the  same parental drug is prepared for IM and
  IV  administration and still studies need to be shown ?(ex diclofenac/ aceclofenac?
  Thanks and Cheers
  Kurani
  
  

  Back to the Top

• On 4 Nov 2014 at 07:56:22, Edward O'Connor (efoconnor.aaa.gmail.com) sent the message
  

  
  Is this in development or discovery?  In discovery, I have seen almost any solvent used.  Some
  solvents can be very toxic and that toxicity is often discounted in discovery.  In development there
  is much more consideration given to limit the toxicity to the API alone and for obvious reasons.  So
  the question to you is are you in discovery or develoment?
  
  

  Back to the Top

• On 4 Nov 2014 at 13:52:23, MHEDHBI Sofiene (vetsof.-at-.yahoo.fr) sent the message
  

  
  All,
  
  Whatever the drug development stages and the specific question raised, please consider the following
  vehicles for the non-clinical use (you can have free access to the original work performed by Gad et
  al):
  
  http://www.afstal.com/medias/File/Ethical/Techniques/Nonclinical%20vehicle%20use%20PDF.pdf
  
  Cheers,
  
  

  Back to the Top

• On 4 Nov 2014 at 13:53:15, Florence Raynaud (Florence.Raynaud.at.icr.ac.uk) sent the message
  

  
  We are in late discovery.
  Many thanks.
  Florence.	
  
  

  Back to the Top

• On 5 Nov 2014 at 09:09:10, yash patel (yashdpatel.-at-.live.com) sent the message
  

  
  Dear Dr. Florence,
  
  It depends on the nature of molecule you are working upon. whether it is water soluble or not. If
  molecule is water insoluble, may use vitamin based surfactants to solubilize the compound. It would
  facilitate the IV/PO administration of formulation for animal studies.
  I hope it helps.
  
  Regards,
  Yash Patel
  
  

  Back to the Top

Copyright 1995-2014 David W. A. Bourne (david@boomer.org)